It is also FDA-authorised under an EUA as a third primary series dose in individuals 12 years old and above who have certain kinds of immunocompromises. The Pfizer/BioNTech bivalent COVID-19 ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Germany's foreign intelligence service in 2020 put at 80%-90% the likelihood that the coronavirus behind the COVID-19 ...

With all the different messages and information about the COVID-19 vaccine, you may be wondering whether your little one ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

Pfizer on Thursday named James List as the head of the drugmaker's Internal Medicine portfolio, where he will oversee the ...

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Pfizer's shot is also approved as a two-dose series administered six months apart. With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes The ACIP has already ...